Abstract
The implementation of therapeutic anticoagulation influences the severity and outcome of patients with coronary artery disease (CAD). This review aims to summarize the current guidelinebased recommendations about the use of new oral anticoagulants (NOACs) in patients with stable CAD (SCAD), acute coronary syndromes (ACS), percutaneous coronary interventions (PCI) and in patients with concomitant atrial fibrillation (AF). The implications of the use of specific NOACs, such as the direct factor Xa inhibitors apixaban and rivaroxaban as well as the direct thrombin inhibitor dabigatran are outlined and compared to the benefits of vitamin k antagonists and antiplatelet agents such as thienopyridines in these settings.
Keywords: Acute coronary syndrome, coronary artery disease, coumadin, novel oral anticoagulation, PCI, vitamin k antagonist, warfarin.
Cardiovascular & Hematological Disorders-Drug Targets
Title:New Oral Anticoagulants in Coronary Artery Disease
Volume: 15 Issue: 2
Author(s): Michael Behnes, Christian Fastner, Uzair Ansari and Ibrahim Akin
Affiliation:
Keywords: Acute coronary syndrome, coronary artery disease, coumadin, novel oral anticoagulation, PCI, vitamin k antagonist, warfarin.
Abstract: The implementation of therapeutic anticoagulation influences the severity and outcome of patients with coronary artery disease (CAD). This review aims to summarize the current guidelinebased recommendations about the use of new oral anticoagulants (NOACs) in patients with stable CAD (SCAD), acute coronary syndromes (ACS), percutaneous coronary interventions (PCI) and in patients with concomitant atrial fibrillation (AF). The implications of the use of specific NOACs, such as the direct factor Xa inhibitors apixaban and rivaroxaban as well as the direct thrombin inhibitor dabigatran are outlined and compared to the benefits of vitamin k antagonists and antiplatelet agents such as thienopyridines in these settings.
Export Options
About this article
Cite this article as:
Behnes Michael, Fastner Christian, Ansari Uzair and Akin Ibrahim, New Oral Anticoagulants in Coronary Artery Disease, Cardiovascular & Hematological Disorders-Drug Targets 2015; 15 (2) . https://dx.doi.org/10.2174/1871529X1502151209111429
DOI https://dx.doi.org/10.2174/1871529X1502151209111429 |
Print ISSN 1871-529X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4063 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial (Diabetes, Obesity and Vascular Disease - An Update)
Current Pharmaceutical Design Proteomic Analysis of Endothelin-1 Targets in the Regulation of Cardiomyocyte Proliferation
Current Topics in Medicinal Chemistry The Effects of Glucagon-Like Peptide Type 1 (GLP-1) and its Analogues in Adipose Tissue: Is there a way to Thermogenesis?
Current Molecular Medicine Auto-Antibodies As Possible Markers and Mediators of Ischemic, Dilated, and Rhythmic Cardiopathies
Current Drug Targets Secondary Prevention of Ischemic Stroke
Current Drug Targets Antioxidative Effects of Rhodiola Genus: Phytochemistry and Pharmacological Mechanisms against the Diseases
Current Topics in Medicinal Chemistry Innate Immunity and the Heart
Current Pharmaceutical Design Critical Determinants of Cardiovascular Risk in Rheumatoid Arthritis
Current Pharmaceutical Design AMPK Activators as Novel Therapeutics for Type 2 Diabetes
Current Topics in Medicinal Chemistry Antitubercular and Antimicrobial Activity of NH4VO3 Promoted 1,4- Dihydropyridine Incorporated 1,3,4-trisubstituted Pyrazole
Letters in Drug Design & Discovery Pragmatic Analysis of Dyslipidemia Involvement in Coronary Artery Disease: A Narrative Review
Current Cardiology Reviews Meet Our Editorial Board Member
Current Medical Imaging TNF alpha Inhibition as Treatment Modality for Certain Rheumatologic and Gastrointestinal Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets Dynamic Role of Microparticles in Type 2 Diabetes Mellitus
Current Diabetes Reviews Duration of Dual Antiplatelet Therapy After Coronary Stenting
Current Pharmaceutical Design Hypertensive Left Ventricular Hypertrophy Regression: Does It Matter?
Current Hypertension Reviews A Dietary Approach for Treating Dyslipidemia and Hyperglycemia
Current Nutrition & Food Science Whole Milk and Full-Fat Dairy Products and Hypertensive Risks
Current Hypertension Reviews Herbal and Traditional Chinese Medicine for the Treatment of Cardiovascular Complications in Diabetes Mellitus
Current Diabetes Reviews Safety Considerations in the Use of Ketorolac for Postoperative Pain
Current Drug Safety